U.S. regulators approved the first generic rival to Johnson & Johnson's Duragesic pain relief skin patch. Mylan Laboratories Inc. will produce several different strengths of the patch, known generically as the
fentanyl transdermal system, and launch the product immediately. Johnson & Johnson's annual sales of the patch total about $1.63 billion.
Mylan, the biggest U.S. maker of generic drugs, had hoped to launch its copycat version last year, but the FDA granted J&J an additional six months of market exclusivity in return for
testing the drug's safety and effectiveness in children.
Has anyone had experience using this?
Did you find this post useful?

3

3